News headlines about Transgenomic (NASDAQ:PRPO) have trended somewhat positive this week, according to Accern. The research firm identifies negative and positive media coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Transgenomic earned a news impact score of 0.14 on Accern’s scale. Accern also assigned media headlines about the biotechnology company an impact score of 44.5474611539156 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

Transgenomic (PRPO) traded up 2.28% on Monday, hitting $4.94. The stock had a trading volume of 4,829 shares. The company’s 50 day moving average price is $8.45 and its 200-day moving average price is $8.45. Transgenomic has a 12-month low of $3.35 and a 12-month high of $47.70. The company’s market cap is $4.42 million.

Separately, ValuEngine lowered Transgenomic from a “sell” rating to a “strong sell” rating in a report on Tuesday, August 1st.

ILLEGAL ACTIVITY WARNING: “Somewhat Positive Press Coverage Somewhat Unlikely to Affect Transgenomic (PRPO) Stock Price” was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this article on another publication, it was stolen and republished in violation of United States and international copyright & trademark legislation. The legal version of this article can be accessed at

About Transgenomic

Precipio, Inc, formerly Transgenomic, Inc, is a biotechnology company. The Company is engaged in advancing personalized medicine for the detection and treatment of cancer, and inherited diseases through its molecular technologies and clinical and research services. The Company operates through its Laboratory Services segment.

Receive News & Stock Ratings for Transgenomic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Transgenomic Inc. and related stocks with our FREE daily email newsletter.